These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29702120)

  • 1. Chinese herbal extract Su-duxing had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis B virus (HBV) in vitro and effectively suppressed HBV replication in mouse model.
    Liu Y; Yao W; Si L; Hou J; Wang J; Xu Z; Li W; Chen J; Li R; Li P; Bo L; Xiao X; Lan J; Xu D
    Antiviral Res; 2018 Jul; 155():39-47. PubMed ID: 29702120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatitis B virus
    Ge FL; Yang Y; Si LL; Li YH; Cao MZ; Wang J; Bai ZF; Ren ZG; Xiao XH; Liu Y
    World J Gastroenterol; 2024 Apr; 30(13):1911-1925. PubMed ID: 38659485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice.
    Yao X; Li Z; Gong X; Fu X; Xiao X; He M; Huang B; Xu Z
    J Ethnopharmacol; 2020 Mar; 249():112366. PubMed ID: 31678415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
    Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
    Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
    Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on mechanism of Chinese Yam polysaccharide synergizing nucleoside analogues against hepatitis B virus through p38 MAPK signaling pathway].
    Li CY; Wu ZH; Zheng Y; Li B; Zhang JC; Lu LX; Xie XQ; He YJ; Yu XH
    Zhongguo Zhong Yao Za Zhi; 2024 May; 49(10):2776-2782. PubMed ID: 38812178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV)
    Ge FL; Si LL; Yang Y; Li YH; Lv ZL; Liu WH; Liao H; Wang J; Zou J; Li L; Li H; Zhang ZL; Wang JB; Lu XC; Xu DP; Bai ZF; Liu Y; Xiao XH
    Front Pharmacol; 2021; 12():756975. PubMed ID: 34776974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
    Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
    Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim.
    Xu HY; Ren JH; Su Y; Ren F; Zhou YJ; Jiang H; Cheng ST; Zhang CR; Chen J
    J Ethnopharmacol; 2020 Jul; 257():112787. PubMed ID: 32224198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
    Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
    Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
    BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.
    Huang H; Zhou W; Zhu H; Zhou P; Shi X
    Toxicol Appl Pharmacol; 2017 May; 323():36-43. PubMed ID: 28322895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavocoxid exerts a potent antiviral effect against hepatitis B virus.
    Pollicino T; Musolino C; Irrera N; Bitto A; Lombardo D; Timmoneri M; Minutoli L; Raimondo G; Squadrito G; Squadrito F; Altavilla D
    Inflamm Res; 2018 Jan; 67(1):89-103. PubMed ID: 29018874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6.
    Chen JX; Shen HH; Niu M; Guo YM; Liu XQ; Han YZ; Zhang YM; Zhao YL; Bai BK; Zhou WJ; Xiao XH
    Virus Res; 2016 Apr; 215():104-13. PubMed ID: 26685094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.
    Yang HY; Zheng NQ; Li DM; Gu L; Peng XM
    Virol J; 2014 Sep; 11():165. PubMed ID: 25224377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
    Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
    Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.